Drug Market To Experience Poor Growth - Impacted By Patent Cliff

BMI View: The attractiveness of the Western Europe region to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma' and particularly for companies selling high-end products, as per-capita spending is substantially higher than in emerging markets. However, BMI believes that drug companies will face many challenges in Western Europe over the next decade, including the need to reduce fiscal deficits, the patent cliff, added regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new

To read the full article, please choose one of the following options: